



Prescriber Signature: __

| STELARA (USTEKINUMAB) PATIENT REFERRAL AND PRESCRIPTION SHEET | | | | | | |
|---|--------|-----------|--|------------------------------|--|--|
| Patient Information | | | | | | |
| Patient Name: | | | Date: | | | |
| DOB: | | | Height: | ☐ inches ☐ cm | | |
| Allergies: | | | | Weight: | □ lbs □ kg | |
| Primary Diagnosis | | | | | | |
| Diagnosis | ICD-10 | Diagnosis | ; | | ICD-10 | |
| ☐ Crohn's Disease | K50.90 | ☐ Plaque | Psoriasis | | L40.0 | |
| ☐ Ulcerative Colitis | K51.90 | ☐ Psoriat | ic Arthritis | | L40.52 | |
| □ Other: | | | | | | |
| Medication Order | | | | | | |
| Stelara (Ustekinumab): Plaque Psoriasis or Psoriatic arthritis: □ Patients weighing < 100kg: 45mg subQ initially and 4 weeks later, follow □ Patients weighing >100kg: 90mg subQ initially and 4 weeks later, follow Crohn's Disease or Ulcerative Colitis: Initial Dosing: □ ≤55kg (<121 lbs.): 260mg IV over 1 hour x 1 dose □ >55kg to 85kg: 390mg IV over 1 hour x 1 dose □ >85 kg: 520mg IV over 1 hour x 1 dose □ >85 kg: 520mg IV over 1 hour x 1 dose | | | | | Refills x one year from date of signature unless indicated below | |
| Skilled nursing to assess and administer via access device as indicated below. Nursing will provide ongoing support as needed. | | | | | | |
| Ancillary Orders (for IV Administration only) | | | | | | |
| ☐ Diphenhydramine: 25mg PO 30 min pre-infusion ☐ Acetaminophen: 650mg PO 30 min pre-infusion ☐ Famotidine: 20 mg PO x1 dose ☐ Other pre-meds: | | | IV Flush Orders: ☐ Peripheral: NS 1-3 mL before/after use ☐ Implanted VAD: NS 5 to 10 mL before/after use and 10 mL post-lab draw. Heparin (100 unit/mL) 3 to 5 mL final flush ☐ CVAD: NS 5 to 10 mL before/after use and 10 mL post-lab draw Heparin (10 units/mL) 3 to 5 mL final flush ☐ Refill x one year | | | |
| ☐ Anaphylaxis Protocol: Epinephrine Auto-Injector dual pack: Adult: 0.3mg Children: 0.15 mg Administer epinephrine IM in the event of anaphylaxis. May repeat x 1 as needed, Call 911. Refill x 1yr | | | | | | |
| Therapy Specific Documentation | | | | Other Required Documentation | | |
| results are available, the following labs will be drawn prior to first infusion: | | | □ Patient Demographics – include insurance information. We will obtain authorization unless the insurance dictates otherwise. □ H&P OR progress note(s) □ Medication List - please list past and present DMARDS and biologics below with dates of discontinue, if applicable | | | |
| Provider Information | | | | | | |
| Provider Name: | | | | Provider Phone: | | |
| Provider NPI: | | | | Provider Fax: | | |
| Provider Address: | | | | | | |
| authorize KabaFusion and its representatives to act as an agent and initiate and execute any insurance prior authorization process for this prescription and any future refills of the same prescription for the national listed above. Lunderstand that Lean revoke this designation at any time by providing written notice to KabaFusion. | | | | | | |

CONFIDENTIALITY NOTICE: The following includes confidential, proprietary information that is the sole exclusive property of KabaFusion Holdings, LLC. No rights in, relating to, or derived from such information are assigned or otherwise transferred by this document, and the recipient of such information is subject to obligations of secrecy to and for the benefit of KabaFusion Holdings, LLC. Any unauthorized use or disclosure of such information is strictly prohibited. This message, together with any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain information that is confidential and prohibited from disclosure. If you are not the intended recipient, you are hereby notified that any dissemination, or copying of this message, or any attachment, is strictly prohibited. If you have received this message in error, please notify the original sender immediately by telephone or by return fax and shred this document along with any other documents. Thank you.

Date: _